Seasonal influenza presents a significant burden on both health and economic fronts, impacting children and adults alike. The narrative review focuses on the cost-effectiveness of cell-based influenza vaccines (QIVc) compared to traditional egg-based vaccines (TIVe/QIVe) in individuals under 65 years of age. It evaluates various cost-effectiveness analyses (CEAs) from multiple countries, assessing the assumptions and methodologies used, while considering the role of QIVc in different demographic groups.
Comparative Effectiveness and Assumptions
The review highlights that CEAs consistently demonstrate the superior cost-effectiveness of QIVc over TIVe and QIVe. The analyses used diverse relative vaccine effectiveness (rVE) estimates, with QIVc showing a relative effectiveness ranging from 8.1% to 36.2% higher than QIVe. The consistency of these findings across different models and assumptions underscores the robustness of the results.
Moreover, the study evaluates various assumptions and approaches used in these analyses. Despite variations in the rVE estimates, the models consistently favor QIVc, indicating a reliable trend towards its cost-effectiveness. This suggests that QIVc is a valuable alternative to traditional egg-based vaccines, particularly in regions with high influenza prevalence.
Global Implications and Recommendations
The review also considers the global implications of adopting cell-based influenza vaccines. It notes that QIVc’s cost-effectiveness is evident across different geographic regions and population segments. This has significant implications for public health policy, suggesting a potential shift towards QIVc to improve health outcomes and reduce economic burdens associated with seasonal influenza.
Given the consistent findings, the review recommends further exploration and adoption of QIVc, especially in countries with high influenza-associated morbidity and mortality rates. Policymakers are encouraged to consider these findings in their vaccination strategies to enhance overall health benefits.
Key Inferences for Policy and Practice
- QIVc presents a cost-effective alternative to TIVe/QIVe, with a higher relative effectiveness ranging from 8.1% to 36.2%.
- The robustness of QIVc’s cost-effectiveness is consistent across various models and geographic regions.
- Adopting QIVc in national vaccination programs could significantly reduce health and economic burdens of seasonal influenza.
- Further research and policy shifts towards QIVc are recommended to enhance public health outcomes.
In conclusion, the narrative review underscores the cost-effectiveness and potential health benefits of cell-based influenza vaccines over traditional egg-based options. It calls for policymakers to consider these findings in their vaccination strategies, highlighting the consistent advantages of QIVc across different scenarios and regions.
Original Article: Hum Vaccin Immunother. 2024 Dec 31;20(1):2351675. doi: 10.1080/21645515.2024.2351675. Epub 2024 Jun 4.
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
